Trial Profile
A Randomized, Multicentre, Open Label, Evaluator Blinded Study to Evaluate Safety and Efficacy of Folitime of Gemabiotech S.A., Versus Gonal-f of Merck Serono, in Patients With Infertility Undergoing ART
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Follitropin alfa (Primary)
- Indications Infertility
- Focus Therapeutic Use
- Sponsors GEMA
- 23 Feb 2017 Status changed from recruiting to completed.
- 10 Jun 2015 New trial record